KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with …
Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA – Deutsch Italia – Italiano APAC – Traditional Chinese USA – español Latin America – español USA – English USA – English
